Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

126.38 -2.83 (-2.19%)
Streaming Delayed Price Updated: 10:23 AM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S ADR

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
43 44 Next >
Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand
Indian pharmaceutical giants, including Sun Pharma and Cipla, seize the opportunity to develop affordable versions of Novo Nordisk's Wegovy weight-loss treatment. With patents set to expire by... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Move Over Magnificent 7, Say Hello to the GRANOLAS
Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods. 
Via InvestorPlace
2 No-Brainer Biotech Stocks to Buy Right Now
These stocks are used to beating the market. 
Via The Motley Fool
Weight-Loss Drugs Vs. Conagra Foods: Company Optimistic Amid Shifting Consumer Demands Influenced By Hunger Suppressing
Conagra Brands' optimistic outlook at a Conference addressing concerns about weight-loss drugs impacting U.S. food companies. Executive backs positivity with Numerator data, citing an 8% rise in... 
Via Benzinga
7 Analysts Assess Novo Nordisk: What You Need To Know
Via Benzinga
Novo Nordisk Unusual Options Activity For February 14
Via Benzinga
NYSE:NVO is not too expensive for the growth it is showing.
Investors seeking growth at a reasonable cost should explore NYSE:NVO. 
Via Chartmill
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Via Benzinga
3 Top Sectors Investment Dollars Are Pouring Into Now: February 2024
Predicting top sectors isn't easy; we usually identify them only in hindsight, but these three stock market segments are rapidly rising. 
Via InvestorPlace
3 Cheap Dividend Stocks to Snatch Up Now
Cheap dividend stocks offer rebound upside paired with an income source that is difficult to beat for most investors. 
Via InvestorPlace
Ozempic Effect: Food Industry Feels The Heat As Weight-Loss Drugs Get Popular, Investors Call For Menu Makeovers
A survey conducted by Bloomberg Markets Live revealed that nearly 75% of the 303 respondents believe that companies selling unhealthy foods should recalibrate their business models. This could involve... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Novo Nordisk Has More Than Ozempic. One of Its Other Treatments Grew 393% Last Year.
It may be best known for its diabetes treatment, Ozempic, but Novo Nordisk has a host of other blockbuster drugs, too. 
Via The Motley Fool
Wealth Generators: 3 Growth Stocks You’ll Regret Not Buying in 2024
Novo Nordisk (NVO), Caterpillar (CAT), and First Solar (FSLR) are the 3 best growth stocks you'll regret now buying in 2024! 
Via InvestorPlace
22 Blue-Chip European Dividend Growth Stocks
A discussion of insights on European dividend growth stocks. 
Via Talk Markets
Meet the Next Trillion-Dollar Companies: Our Top 7 Picks
These future trillion-dollar stocks are on their way to mythic valuation, supported by strong underlying fundamentals and prospects. 
Via InvestorPlace
UK Becomes First Major Market for Eli Lilly's Mounjaro Prefilled Pen For Tackling Obesity
Eli Lilly's popular obesity and diabetes drug, Mounjaro (tirzepatide), hits the UK market this week. Superdrug and Simple Pharmacy offer accessible prescriptions for NHS and private patients. 
Via Benzinga
What's Gaining Popularity Among US Teens Battling Obesity? Novo Nordisk's Weight Loss Drug Wegovy
Rise of adolescent usage of Novo Nordisk's Wegovy for pediatric obesity. Surging demand among families, but concerns linger on the impact of weight-loss drugs on growing children's development. 
Via Benzinga
7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution
Obesity drug sales boomed in 2023 and will continue in 2024. That could make these weight loss stocks even more attractive. 
Via InvestorPlace
1 Potential Catalyst That Could Light a Fire Under Novo Nordisk's Stock This Year
Don't let the stock's high price deceive you -- Novo Nordisk can still make for a great investment. 
Via The Motley Fool
Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?
It faces both clinical and competitive barriers, but they might not matter. 
Via The Motley Fool
Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report
Kerrisdale Capital has released a short report, making clear why it is betting against ALT stock. Here's why Altimmune is likely in trouble. 
Via InvestorPlace
Altimmune Stock Sinks As Kerrisdale Capital Announces Short Position: 'Obvious Dead End'
Altimmune shares are trading lower Tuesday after short-selling investment firm Kerrisdale Capital published a new research report on the stock and announced a short position 
Via Benzinga
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.
There's more for investors to get excited about in the biopharma world than just weight-loss drugs. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Novo Nordisk's Weight Loss Drugs Ozempic, Wegovy Show Promise For Diabetic Patients Undergoing Hip Replacement
Findings on diabetes and weight loss drugs in hip replacement. Novo Nordisk's Ozempic shows a 44% reduction in joint infections, and Wegovy proves safe, reducing complications. 
Via Benzinga
2 Value Stocks With Monster Yields
These two low-priced large-cap stocks sport ginormous yields. 
Via The Motley Fool
Novo Nordisk's Magic Run Continues Even With Increasing Competition
Novo Nordisk's Q4 earnings were rock solid as momentum in the diabetes and obesity markets continued to fuel growth. 
Via The Motley Fool
Novo Nordisk, Eli Lilly Stride To Boost Supply Shortage For Newly Found Holy Grail Of Miraculous Weight Loss Drugs
Challenges and updates in the weight loss drug market, as Novo Nordisk and Eli Lilly address supply shortages for Wegovy and Mounjaro. Strategies to meet the increasing demand and potential market... 
Via Benzinga
Wall Street's Next Stock-Split Stocks Are Liable to Be Familiar Names
Nine high-profile stocks -- Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk -- have split since mid-2021. Two of these companies appear ready... 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
43 44 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.